These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2860659)

  • 1. Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration.
    Christensen AV; Arnt J; Svendsen O
    Psychopharmacology Suppl; 1985; 2():182-90. PubMed ID: 2860659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics.
    Christensen AV; Arnt J; Hyttel J; Larsen JJ; Svendsen O
    Life Sci; 1984 Apr; 34(16):1529-40. PubMed ID: 6144029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J; Christensen AV
    J Neural Transm Suppl; 1983; 18():157-64. PubMed ID: 6135740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.
    Arnt J
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):97-104. PubMed ID: 2864641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions.
    Arnt J; Hyttel J
    Eur J Pharmacol; 1984 Jul; 102(2):349-54. PubMed ID: 6148252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor pharmacology. Its use in neuroleptic research.
    Hyttel J
    Acta Psychiatr Belg; 1987; 87(5):535-51. PubMed ID: 2897759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prolonged treatment with neuroleptics on dopamine D-1 and D-2 receptor density in corpus striatum of mice.
    Hyttel J
    Acta Pharmacol Toxicol (Copenh); 1986 Nov; 59(5):387-91. PubMed ID: 2880451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.
    Arnt J; Hyttel J
    Psychopharmacology (Berl); 1985; 85(3):346-52. PubMed ID: 2860689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats.
    Arnt J; Bøgesø KP; Hyttel J; Meier E
    Pharmacol Toxicol; 1988 Mar; 62(3):121-30. PubMed ID: 3259694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats.
    Arnt J; Hyttel J; Bach-Lauritsen T
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):319-24. PubMed ID: 2879412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics.
    Arnt J; Christensen AV
    Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the interaction between D1 and D2 receptors in a drug discrimination paradigm.
    Williams JE; Sutherland JV; Woolverton WL
    Behav Neural Biol; 1990 May; 53(3):378-92. PubMed ID: 1972014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scopolamine modulates apomorphine-induced behavior in rats treated with haloperidol or SCH 23390.
    Butkerait P; Friedman E
    Eur J Pharmacol; 1988 Mar; 148(2):269-72. PubMed ID: 2897925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Behavioral pharmacological investigation and clinical consideration of the inhibitory potencies of psychotropic drugs against the D-1 and D-2 dopamine receptors].
    Kazawa T
    Yakubutsu Seishin Kodo; 1986 Sep; 6(3):327-37. PubMed ID: 2949452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
    Andersen PH
    Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM; Bruno JP
    Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.